The US Food and Drug Administration has issued a safety communication warning about potential premature battery depletion in Boston Scientific’s Accolade pacemaker devices, which may require earlier-than-expected device replacement. The FDA alert advises healthcare providers to monitor affected patients more closely and consider device replacement protocols.
Key takeaways
- FDA identifies battery longevity issues in specific Accolade pacemaker models requiring enhanced monitoring
- Healthcare providers must implement more frequent device checks for affected patients
- Early device replacement may be necessary to prevent loss of pacing function
Pacemaker Safety Alerts by Device Type
FDA safety communications for cardiac devices, 2023-2024
Source: FDA Medical Device Safety Communications | Georgian Medical Journal News
Battery Depletion Mechanism Identified
The FDA’s Center for Devices and Radiological Health has identified specific technical issues affecting battery longevity in certain Accolade pacemaker models. Boston Scientific has collaborated with regulators to characterize the failure mode and develop monitoring protocols.
The battery depletion occurs through an accelerated discharge mechanism that may not be detected through standard device interrogation intervals. This creates a potential safety risk where patients could experience sudden loss of pacing support.
Clinical Monitoring Recommendations
Healthcare providers managing patients with affected Accolade devices should implement enhanced surveillance protocols, according to the FDA safety communication. The agency recommends more frequent device interrogations to detect early signs of accelerated battery depletion.
Clinicians should establish direct communication with affected patients to ensure they understand the importance of regular follow-up appointments. The enhanced monitoring protocol may require clinical practice modifications for electrophysiology and cardiology services managing these patients.
Enhanced monitoring protocols required for affected Accolade pacemaker patients to detect accelerated battery depletion before device failure
— FDA Center for Devices and Radiological Health (FDA Safety Communication, 2024)
Device Replacement Protocols
The FDA guidance outlines criteria for determining when early device replacement should be considered for affected patients. Healthcare providers must weigh the risks of premature device failure against the procedural risks of early replacement surgery.
Boston Scientific has committed to providing technical support and replacement devices for patients meeting the FDA’s replacement criteria. The company is working with healthcare facilities to ensure appropriate inventory management for replacement procedures.
What this means
Frequently asked questions
Which Accolade pacemaker models are affected?
The FDA alert covers specific Accolade model numbers that Boston Scientific has identified as having potential battery longevity issues. Patients should consult their cardiologist to determine if their device is affected.
What symptoms might indicate pacemaker battery problems?
Symptoms may include dizziness, fatigue, shortness of breath, or fainting spells, particularly in patients who are pacemaker-dependent. However, battery depletion may occur without obvious symptoms.
How often should affected patients have device checks?
The FDA recommends more frequent monitoring than standard protocols, but specific intervals should be determined by the treating cardiologist based on individual patient factors and device status.
The FDA continues to work with Boston Scientific to monitor the situation and may issue additional guidance as more data becomes available. Healthcare providers are encouraged to report any adverse events related to Accolade pacemaker devices through the FDA’s MedWatch reporting system to support ongoing safety surveillance efforts.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
